1512P - Clinicopathologic features and long-term follow-up of metastatic gastrointestinal stromal tumor (GIST) patients (pts) with durable response (≥ 5 ye...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
GIST
Sarcoma
Presenter Cesar Serrano
Citation Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387
Authors C. Serrano1, A. Lopez Pousa2, I. Pajares3, C. Valverde Morales1, J. Duran4, J. Rubió-Casadevall5, M.J. Safont6, V. Martinez7, R. Díaz Beveridge8, A. Estival9, D. Vicente Baz10, A. Sebio Garcia2, N. Hindi11, S. Landolfi12, D. Olivares1, A. Garcia-Valverde1, P. Ledesma13, J. Arribas14, J. Carles Galceran1, J. Martin Broto11
  • 1Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 2Medical Oncology, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 3Medical Oncology, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 4Medical Oncology, Hospital Universitario Son Espases, 07010 - Palma/ES
  • 5Medical Oncology, Hospital Josep Trueta, Gerona/ES
  • 6Medical Oncology, Hospital General de Valencia, Valencia/ES
  • 7Medical Oncology, Hospital La Paz, Madrid/ES
  • 8Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 9Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 10Medical Oncology, Hospital Universitario Virgen Macarena, 41003 - Sevilla/ES
  • 11Medical Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 12Surgical Pathology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 13Sofpromed Investigación Clínica, GEIS, Palma/ES
  • 14Preclinical Program, Vall d'Hebron University Hospital, 8035 - Barcelona/ES

Abstract

Background

IM achieves disease control in most metastatic GIST pts, typically about 18 months. Interestingly, ∼15% GIST pts remain on IM beyond 5 years of continuous treatment. To date, clinicopathologic features predictive of long-term benefit to IM remain largely unknown.

Methods

We analyzed clinical, pathological and molecular characteristics, and long-term outcomes in metastatic GIST pts treated with continuous daily dosing of frontline IM in a cohort of pts benefiting ≥ 5 years, compared with a control group obtained from a national GEIS database.

Results

We found 41 IM long-term responders (IM-LTR) and 71 control cases (CC) with a median time on IM of 90.6 and 18.2 months, respectively. Compared to CC, IM-LTR were younger (59 vs 64 years, p = 0.040), fitter at diagnosis (performance status (PS) 0-1: 100% vs 82.2%, p 

Conclusions

Clinical and inherently biological tumor characteristics define a subset of GIST pts with increased likelihood to achieve durable benefit from IM. Molecular studies are needed to better identify these pts at treatment initiation.

Clinical trial identification

Legal entity responsible for the study

Spanish Group of Sarcoma Research (GEIS)

Funding

Spanish Group of Sarcoma Research (GEIS)

Disclosure

All authors have declared no conflicts of interest.